Kisunla: A New Breakthrough for Alzheimer’s Disease The FDA’s approval of Kisunla (donanemab-azbt) marks a significant advancement in the treatment of early-stage Alzheimer’s disease. Kisunla was developed by Eli Lilly, and this new
What is Compounding? Today, compounding is a practice generally conducted by a licensed pharmacist or outsourcing facility requiring discipline and precision. The core demand for compounding pharmacies is the necessity of a formulation
On May 24, 2024, the FDA approved Onyda XR (clonidine hydrochloride), a liquid non-stimulant medication for attention deficit hyperactivity disorder (ADHD). Developed by Tris Pharma, Onyda XR is a centrally acting alpha 2
On July 13, 2023, the FDA approved the first over-the-counter birth control called ‘Opill’. An increased availability of hormonal birth control without a prescription may increase access and remove the barriers that individuals
On July 18th, 2023, the FDA approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) in neonates and infants born during or entering their first RSV season, and in children up